Aurobindo Pharma arm CuraTeQ gets positive EMA opinion for biosimilar Zefylti

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received a positive CHMP opinion for its filgrastim biosimilar, Zefylti, intended to treat neutropenia and mobilize peripheral progenitor cells. Zefylti is CuraTeQ's first biosimilar to receive this positive opinion. Three additional biosimilars are currently under review with EMA and UK-MHRA, expected to be available next year.

Dec 16, 2024 - 22:30
Aurobindo Pharma arm CuraTeQ gets positive EMA opinion for biosimilar Zefylti

Join our WhatsApp Community to receive travel deals, free stays, and special offers!
- Join Now -

Join our WhatsApp Community to receive travel deals, free stays, and special offers!
- Join Now -

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received a positive CHMP opinion for its filgrastim biosimilar, Zefylti, intended to treat neutropenia and mobilize peripheral progenitor cells. Zefylti is CuraTeQ's first biosimilar to receive this positive opinion. Three additional biosimilars are currently under review with EMA and UK-MHRA, expected to be available next year.
Read More